Skip to main content

Recordati-Industria Chimica Value Stock - Dividend - Research Selection

Recordati-Industria Chimica e Farmaceutica S.p.A.

ISIN: IT0003828271, WKN: A0EABR

Market price date: 22.01.2021
Market price: 41,24 EUR




Recordati-Industria Chimica e Farmaceutica S.p.A. Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 20-04-2020
Cash flow
Net operating cash flow 334.027.000
Capital Expenditures -458.445.000
Free cash flow -124.418.000
Balance sheet
Total Equity 1.198.580.000
Liabilities & Shareholders equity 2.808.930.000
Income statement
Net income 368.825.000
Eps (diluted) 1,760
Diluted shares outstanding 209.560.000
Net sales/revenue 1.481.850.000

Fundamental ratios calculated on: 22-01-2021

Ratios
Key figures 22-01-2021
Cash flow
P/C 25,87
   
P/FC -69,46
Balance sheet
ROI13,13
ROE42,67
Income statement
P/E23,43
Div. Yield0,00%
P/B7,21
P/S5,83


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolRER1.F
Market Capitalization10.481.812.480,00 USD
CountryItaly
IndicesNO INDEX
SectorsPharma
Raw Data SourceIFRS in Millionen EUR
Stock Split
Internetwww.recordati.com


Description of the company

Recordati is a growing international pharmaceutical group. It actively seeks new opportunities and faces the challenges of a constantly changing marketplace with determination.

 

Recordati is a well-established growing international pharmaceutical group listed on the Italian Stock Exchange (now part of the London Stock Exchange) since 1984. The Group has its headquarters in Milan and is one of the oldest Italian pharmaceutical companies. Since it was founded in 1926 Recordati has grown constantly for more than ninety years thanks to the success of its products and to its strategy for growth and development based on internationalization and diversification through an acquisition strategy initiated in the 1990’s and still ongoing. It actively seeks new opportunities and faces the challenges of a constantly changing marketplace with determination. In 2017 the group generated revenues of € 1,288.1 million and has a staff of 4,176 employees.

 

Today the company has many subsidiaries, both in Europe and outside Europe. In addition to the countries in Western Europe the Group is also directly present in the Czech Republic and Slovakia, Romania, Poland, Russia and the other countries belonging to the Commonwealth of Independent States (C.I.S.), Ukraine, Turkey, Tunisia, U.S.A., Canada, Mexico and in some South American countries. Recordati sells its products in 135 markets both directly and through license agreements.

 

In addition to its geographical expansion the Group has enriched its product portfolio by developing its own pipeline of products and by entering the segment dedicated to rare diseases. Recordati develops, produces and sells drugs for the treatment of rare diseases through Orphan Europe and Recordati Rare Diseases, two companies dedicated mainly to metabolic deficiencies of a genetic nature.

 

The Group’s most important products are those, in the cardiovascular therapeutic area based on lercanidipine, a latest generation calcium channel blocker indicated for the treatment of hypertension, discovered and entirely developed in the Recordati research laboratories, and its combination with enalapril, a widely prescribed ACE inhibitor. The Group’s presence in this therapeutic area was further strengthened with the acquisition of the products based on metoprolol, a beta-blocker mainly indicated for the control of a range of conditions including hypertension, angina pectoris, disturbances of cardiac rhythm, maintenance treatment after myocardial infarction, and functional heart disorders with palpitations.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.recordati.com